A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma

Summary

This is a phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in subjects diagnosed with follicular lymphoma (FL) that is relapsed or refractory to either chemotherapy or radioimmunotherapy (RIT).

Timeline

Start

2019-12-18

Primary completion

2021-10-31

Completion

2022-03-31

Drugs

Indications